Woodham Lane, New Haw, Addlestone, Surrey KT15 3LS Telephone +44 (0)1932 336911

Post Authorisation Assessments

Zelys 1.25 mg Chewable Tablets for Dogs Vm 15052/5051

•	July 2024	Tightening the specification limit at shelf life for the tests
		of loss on drying, assay and related substances.
•	24 June 2024	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
•	21 November 2023	Tightening the specification limit for the test of loss on
		drying.
		Tightening the specification limit for the test of assay.
		Tightening the specification limit for the test of related
		substances.
•	07 November 2023	Submission of an updated CEP for pimobendan for
		veterinary use.
•	11 May 2023	Increase in the shelf life of the finished product in blister
		presentation from 2 years to 3 years.
•	14 March 2022	Change in the specification limits of the immediate
		packaging of the finished product.
•	21 October 2022	Change in the address of the MAH from Unit 3 Anglo
		Office Park, White Lion Road Amersham,
		Buckinghamshire HP7 9FB to Explorer House, Mercury
		Park, Wycombe Lane, Wooburn Green, High Wycombe,
		Buckinghamshire, HP10 0HH, United Kingdom.
•	04 August 2022	Unlimited renewal.
•	11 May 2021	Change in the invented names of the veterinary
		medicinal products from Zelys Vet 1.25 mg Chewable
		Tablets for Dogs, Zelys Vet 5 mg Chewable Tablets for
		Dogs and Zelys Vet 10 mg Chewable Tablets for Dogs to
		Zelys 1.25 mg Chewable Tablets for Dogs, Zelys 5 mg
		Chewable Tablets for Dogs and Zelys 10 mg Chewable
		Tablets for Dogs in DK, FI, NO, and SE.
•	28 April 2021	Deletion of a therapeutic indication.
•	31 March 2021	Minor change to an approved test procedure for the
		active substance used in the manufacturing process of
		the active substance.
•	21 May 2020	Addition of a new container for the finished product.
		Minor change in the manufacturing process of an
		immediate release solid oral dosage form.
		Change in the specification of the finished product to
		update appearance (single scored).
		Changes in scoring/break lines intended to divide into
		equal doses.
		Minor adjustments of the quantitative composition of the
		finished product with respect to excipients.
		Minor adjustments of the quantitative composition of the

	finished product with respect to excipients. Change in the SPC, labelling or package leaflet due to new data.
• 01 August 2019	Submission of an updated Ph. Eur. certificate of suitability from an already approved manufacturer.
• 23 May 2019	Replacement of a site where batch control/testing takes place